Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
A Novel Approach to Identify Treatment Subgroups for Cardiometabolic Diseases
EF 2022-23
Résumé
Supervisor: Dr. Guillaume Paré, McMaster University
Medical treatment decisions involve a balance of risks and benefits. While these risks and benefits are typically well defined for the general population, they are less clear for patient subgroups. For example, the effectiveness of cholesterol lowering medications in reducing the risk of heart disease may vary across subgroups of individuals based on age, sex, and other disease states. This information is important to know, as it can help healthcare providers tailor treatments to patients based on their clinical profiles.
To identify subgroups of patients that are more or less likely to benefit from treatments, the Mendelian Randomization (MR) framework will be used. MR uses genetic variants related to a risk factor to determine how the risk factor is causally related to a disease. The use of genetic variants is key to the technique's ability to determine a causal effect rather than a simple association. This is because genetic variants are randomly allocated prior to birth and eliminate the involvement of common confounding variables such as environmental factors.
We will be adapting the traditional MR framework to examine the relationship between risk factors and diseases across different biomarker levels using the UK Biobank database. For example, the effect of blood cholesterol levels on the risk of heart disease will be assessed for patients with different blood glucose levels. If cholesterol levels are not found to affect heart disease risk for patients with certain blood glucose levels, then it could mean that these individuals may actually derive more benefit by withdrawing from cholesterol-lowering therapy, avoiding the risk of medication side effects. This novel MR methodology will open a new paradigm of studies for determining treatment effects in patient subgroups and help tailor treatments to individual patients.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
474551
Name
Man Alice P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
A Novel Approach to Identify Treatment Subgroups for Cardiometabolic Diseases
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cardiometabolic Disease; Genetic Epidemiology; Mendelian Randomization; Precision Medicine
Abstract
Supervisor: Dr. Guillaume Paré, McMaster University
Medical treatment decisions involve a balance of risks and benefits. While these risks and benefits are typically well defined for the general population, they are less clear for patient subgroups. For example, the effectiveness of cholesterol lowering medications in reducing the risk of heart disease may vary across subgroups of individuals based on age, sex, and other disease states. This information is important to know, as it can help healthcare providers tailor treatments to patients based on their clinical profiles.
To identify subgroups of patients that are more or less likely to benefit from treatments, the Mendelian Randomization (MR) framework will be used. MR uses genetic variants related to a risk factor to determine how the risk factor is causally related to a disease. The use of genetic variants is key to the technique's ability to determine a causal effect rather than a simple association. This is because genetic variants are randomly allocated prior to birth and eliminate the involvement of common confounding variables such as environmental factors.
We will be adapting the traditional MR framework to examine the relationship between risk factors and diseases across different biomarker levels using the UK Biobank database. For example, the effect of blood cholesterol levels on the risk of heart disease will be assessed for patients with different blood glucose levels. If cholesterol levels are not found to affect heart disease risk for patients with certain blood glucose levels, then it could mean that these individuals may actually derive more benefit by withdrawing from cholesterol-lowering therapy, avoiding the risk of medication side effects. This novel MR methodology will open a new paradigm of studies for determining treatment effects in patient subgroups and help tailor treatments to individual patients.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Man, Alice P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~